The challenge of HIV sequence diversity in the envelope glycoprotein
One of the major characteristics of the human immunodeficiency viruses (HIVs) is their extremely high genetic variability, which makes HIV one of the fastest evolving among many other human pathogens. Viral heterogeneity is one of the classical means by which HIV evades the host immune system, and also leads to the resistance to various antiretroviral regimens. Highly active antiretroviral therapy to treat HIV-infected patients is mainly based on a combination of protease and reverse transcriptase inhibitors. However, resistance to these drugs, the persistence of latent viral reservoirs and long-term toxicities require the continuous need to improve these classes of drugs and to develop new drugs with other targets. Therefore, a new generation of drugs has been recently developed to inhibit viral entry into the cell.
KeywordsHuman Immunodeficiency Virus Envelope Glycoprotein Fusion Inhibitor Entry Inhibitor Gp120 Envelope Glycoprotein
Unable to display preview. Download preview PDF.
- 11.Vergne L, Bourgeois A, Mpoudi-Ngolle E, Mougnutou R, Mbuagbaw J, Liegeois F, Laurent C, Butel C, Zekeng L, Delaporte E et al. (2003) Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology 310: 254–266PubMedGoogle Scholar
- 12.Leitner T, Korber B, Daniels M, Calef C, Foley B (2005) HIV-1 subtype and circulating recombinant form (CRF) reference sequences. In: T Leitner, B Foley, B Hahn, P Marx, F McCutchan, J Mellors, S Wolinsky, B Korber (eds) HIV sequence compendium 2005, Los Alamos National Laboratory, Los Alamos, 41–48Google Scholar
- 16.Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert-Ajaka I, Simon F, Saragosti S, Brun-Vezinet F (1997) Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 71: 8893–8898PubMedGoogle Scholar
- 17.Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB et al. (2005) Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192: 30–36PubMedCrossRefGoogle Scholar
- 18.Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J et al. (2000) Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38: 3919–3925PubMedGoogle Scholar
- 19.Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V et al. (2000) Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitornaive individuals worldwide. HIV Variant Working Group. AIDS 14: 1489–1495PubMedCrossRefGoogle Scholar
- 21.Adje-Toure C, Bile CE, Borget MY, Hertog K, Maurice C, Nolan ML, Nkengasong JN (2003) Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d’Ivoire. J Acquir Immune Defic Syndr 34: 111–113PubMedCrossRefGoogle Scholar
- 25.Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, Courgnaud V, Seng T, Matton, Molinier S et al. (1999) Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr 20: 115–121Google Scholar
- 26.Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J et al. (2002) Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 185: 1244–1250PubMedCrossRefGoogle Scholar
- 28.Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V (2004) Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 74: 21–28PubMedCrossRefGoogle Scholar
- 29.Roman F, Gonzalez D, Lambert C, Deroo S, Fisher A, Baurith T, Stauub T, Boulme R, Arendt V, Schneider F et al. (2003) Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 33: 134–139PubMedCrossRefGoogle Scholar